ArticleMolecular neurobiology2026
Dexpanthenol Attenuates High Fructose Corn Syrup-Induced Brain Injury by Modulating Oxidative Stress, Neuroinflammation, Apoptotic Signaling and Amyloidogenic Gene Expression.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
High fructose corn syrup (HFCS) consumption may lead to oxidative stress-related neurodegeneration. Dexpanthenol (DEX), with antioxidant and cytoprotective properties, may exert neuroprotective effects; however, its efficacy against HFCS-induced neurotoxicity remains unclear. This study examined DEX's effects against HFCS-induced neurotoxicity across multiple pathways. Rats were randomly assigned to four experimental groups (n = 8, for each group): Control, HFCS (20%, for 8 weeks), HFCS + DEX (500 mg/kg), and DEX. Brain tissues were analyzed by histopathology, immunohistochemistry (tumor necrosis factor-α; TNF-α and caspase-3), biochemical assays, and RT-qPCR of genes related to mitochondrial biogenesis, antioxidant defense, apoptosis, inflammation, neurotrophic signaling (brain-derived neurotrophic factor; BDNF), and amyloidogenic gene expression (amyloid precursor protein; APP, beta-site APP cleaving enzyme 1; BACE1, presenilin-1,2; PSEN1,2). HFCS significantly increased total oxidant status (TOS) (p < 0.01) along with pronounced histopathological damage including gliosis, neuronal degeneration, and Purkinje cell loss. It also increased TNF-α and caspase-3 immunoreactivity (p < 0.001), upregulated APP, BACE1, PSEN1 and PSEN2 gene expression, and reduced BDNF expression. DEX significantly reduced TOS and oxidative stress index (OSI) (p < 0.001), decreased TNF-α and caspase-3 immunoreactivity (p < 0.001), increased BDNF expression (p < 0.01), and significantly downregulated BACE1 and PSEN1 gene expression (p < 0.05). These findings suggest that DEX may attenuate HFCS-associated brain injury by modulating oxidative stress, inflammatory responses and apoptotic signaling, and amyloidogenic gene-expression changes.
Indexed as
Identifiers
42709289What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.